CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
Status:
RECRUITING
Trial end date:
2027-10-20
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with severe aplastic anemia